Alnylam Act^® hATTR Amyloidosis Sponsored Testing Program

Patients with at least one hATTR high index of suspicion indicators (below) are eligible for testing:

• Family history of hATTR amyloidosis
• Positive imaging consistent with amyloid (technetium, CMR, strain echo)
• Positive biopsy for TTR amyloid

OR

Patients with at least two hATTR index of suspicion indicators (below) are eligible for testing:

• Sensory and/or motor neuropathy (e.g., neuropathic pain, altered sensation, numbness and tingling, muscle weakness, impaired balance, difficulty walking, carpal tunnel syndrome-associated neuropathy, EMG/NCS abnormalities)
• Autonomic dysfunction (e.g., nausea and vomiting, changes in GI motility, orthostatic hypotension, sexual dysfunction, bladder dysfunction)
• Heart disease (e.g., cardiomyopathy, restrictive physiology, hypertrophy, arrhythmias, conduction abnormalities, heart failure, abnormal cardiac imaging)
• Musculoskeletal indicators (e.g., history of carpal tunnel syndrome, back pain/lumbar spinal stenosis, rotator cuff injury)
• Renal abnormalities (e.g., renal insufficiency and/or proteinuria)
• Ocular changes (e.g., vitreous opacity, glaucoma, dry eyes, ocular amyloid angiopathy, retinal detachment)